Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Cyclo Therapeutics Inc (NQ: CYTH )

0.6875 -0.0425 (-5.82%)
Streaming Delayed Price Updated: 10:21 AM EST, Nov 25, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Cyclo Therapeutics Inc

< Previous 1 2 3 4 5 6 Next >
Cyclo Therapeutics Names Preeminent Neuroscientist and World-Renowned Researcher, Cynthia A. Lemere, PhD, as Senior Advisor for Advancement of Alzheimer’s Disease Asset
From Cyclo Therapeutics, Inc.
Via Business Wire
Cyclo Therapeutics Recognizes Niemann-Pick Disease Awareness Month Highlighting Need for Broader Awareness and Support for Research to Find a Treatment
From Cyclo Therapeutics, Inc.
Via Business Wire
Cyclo Therapeutics Announces Abstract Accepted for Poster Presentation at the 14th International Congress of Inborn Errors of Metabolism (ICIEM)
From Cyclo Therapeutics, Inc.
Via Business Wire
Cyclo Therapeutics to Participate in the 2021 Virtual Cyclodextrin Conference Hosted by CycloLab
From Cyclo Therapeutics, Inc.
Via Business Wire
Cyclo Therapeutics Appoints Lise Lund Kjems, MD, PhD as Chief Medical Officer
From Cyclo Therapeutics, Inc.
Via Business Wire
Cyclo Therapeutics to Present at the Oppenheimer Fall Healthcare Life Sciences and MedTech Summit
From Cyclo Therapeutics, Inc.
Via Business Wire
Cyclo Therapeutics to Present at H.C. Wainwright 23rd Annual Global Investment Conference
From Cyclo Therapeutics, Inc.
Via Business Wire
Cyclo Therapeutics Provides Business Update and Reports Second Quarter 2021 Financial Results
From Cyclo Therapeutics, Inc.
Via Business Wire
Cyclo Therapeutics' Trappsol Shows Early Safety, Efficacy In Genetic Disorder
Cyclo Therapeutics Inc (NASDAQ: CYTH) has announced new data from its Phase 1 extension study evaluating Trappsol Cyclo Niemann-Pick Disease Type C1 (NPC), a... 
Via Benzinga
Cyclo Therapeutics Announces New Positive Safety and Efficacy Data from Ongoing Phase 1 Open-Label Extension Study of Trappsol® Cyclo™ for the Treatment of Niemann-Pick Disease Type C1
From Cyclo Therapeutics, Inc.
Via Business Wire
Cyclo Therapeutics Commences Commercial-Scale Manufacturing for Trappsol® Cyclo™
From Cyclo Therapeutics, Inc.
Via Business Wire
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Gainers vTv Therapeutics (NASDAQ:VTVT) shares rose 30.08% to $3.07 during Tuesday's pre-market session. The company's market cap stands at $251.7 million. Adial... 
Via Benzinga
Cyclo Therapeutics to Present at the 2021 NPC Patient and Family Conference Hosted by the Australian NPC Disease Foundation
From Cyclo Therapeutics, Inc.
Via Business Wire
Cyclo Therapeutics Shares Move Higher On Kickstart Of Late-Stage NPC Trial With Trappsol Cyclo
Cyclo Therapeutics Inc (NASDAQ: CYTH) has commenced its pivotal Phase 3 study (TransportNPC) evaluating Trappsol Cyclo for Niemann-Pick Disease Type C1 (NPC1). The... 
Via Benzinga
Cyclo Therapeutics Commences Patient Enrollment in TransportNPC, a Pivotal Phase 3 Study Evaluating Trappsol® Cyclo™ in Niemann-Pick Type C1
From Cyclo Therapeutics, Inc.
Via Business Wire
Cyclo Therapeutics Announces Launch of New Website
From Cyclo Therapeutics, Inc.
Via Business Wire
12 Health Care Stocks Moving In Monday's After-Market Session
Gainers RAPT Therapeutics (NASDAQ:RAPT) s... 
Via Benzinga
Cyclo Therapeutics Announces Inclusion in the Russell 2000® Index
From Cyclo Therapeutics, Inc.
Via Business Wire
Cyclo Therapeutics to Present at the JMP Securities Life Sciences Conference
From Cyclo Therapeutics, Inc.
Via Business Wire
12 Health Care Stocks Moving In Monday's Pre-Market Session
Gainers Strongbridge Biopharma (NASDAQ:SBBP) stock moved upwards by 14.1% to $2.75 during Monday's pre-market session. The market value of their outstanding shares is... 
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
Gainers Gracell Biotechnologies (NASDAQ:GRCL) shares rose 21.25% to $17.69 during Friday's regular session. Trading volume for Gracell Biotechnologies's stock is... 
Via Benzinga
Cyclo Therapeutics to Participate in the M-Vest Virtual Conference Series: Alzheimer’s Disease Panel
From Cyclo Therapeutics, Inc.
Via Business Wire
Cyclo Therapeutics Provides Business Update and Reports First Quarter 2021 Financial Results
From Cyclo Therapeutics, Inc.
Via Business Wire
Cyclo Therapeutics Appoints Lori McKenna Gorski as Global Head of Patient Advocacy
From Cyclo Therapeutics, Inc.
Via Business Wire
Cyclo Therapeutics Announces Design of Pivotal Phase 3 Study Evaluating Trappsol® Cyclo™ in Niemann-Pick Type C1
From Cyclo Therapeutics, Inc.
Via Business Wire
55 Biggest Movers From Friday
Gainers Brooklyn ImmunoTherapeutics, Inc. (NYSE: BTX) jumped 45.5% to close at $49.80 on Friday after dropping around 22% on Thursday. Brooklyn ImmunoTherapeutics acquired... 
Via Benzinga
Cyclo Therapeutics to Proceed with IND Filing for Phase 2 Trial Using Intravenous Trappsol® Cyclo™ in Alzheimer’s Disease
From Cyclo Therapeutics, Inc.
Via Business Wire
12 Health Care Stocks Moving In Monday's After-Market Session
Gainers Intec Pharma (NASDAQ:NTEC) shares increased by 7.67% to $4.35 during Monday's after-market session. Intec Pharma's trading volume hit 412 shares by close,... 
Via Benzinga
< Previous 1 2 3 4 5 6 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.